Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
- PMID: 36976301
- DOI: 10.1093/cid/ciad181
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
Abstract
Background: Severely immunocompromised patients are at risk for prolonged or relapsed Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We aimed to evaluate efficacy and safety of combination treatment in immunocompromised COVID-19 patients.
Methods: We included all immunocompromised patients with prolonged/relapsed COVID-19 treated with combination therapy with 2 antivirals (remdesivir plus nirmatrelvir/ritonavir, or molnupiravir in case of renal failure) plus, if available, anti-spike monoclonal antibodies (mAbs), between February and October 2022. The main outcomes were virological response at day 14 (negative Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] swab) and virological and clinical response (alive, asymptomatic, with negative SARS-CoV-2 swab) at day 30 and the last follow-up.
Results: Overall, 22 patients (Omicron variant in 17/18) were included: 18 received full combination of 2 antivirals and mAbs and 4 received 2 antivirals only; in 20 of 22 (91%) patients, 2 antivirals were nirmatrelvir/ritonavir plus remdesivir. Nineteen (86%) patients had hematological malignancy, and 15 (68%) had received anti-CD20 therapy. All were symptomatic; 8 (36%) required oxygen. Four patients received a second course of combination treatment. The response rate at day 14, day 30, and last follow-up was 75% (15/20 evaluable), 73% (16/22), and 82% (18/22), respectively. Day 14 and 30 response rates were significantly higher when combination therapy included mAbs. Higher number of vaccine doses was associated with better final outcome. Two patients (9%) developed severe side effects (bradycardia leading to remdesivir discontinuation and myocardial infarction).
Conclusions: Combination therapy including 2 antivirals (mainly remdesivir and nirmatrelvir/ritonavir) and mAbs was associated with high rate of virological and clinical response in immunocompromised patients with prolonged/relapsed COVID-19.
Keywords: anti-CD20 treatment; anti–SARS-CoV-2 monoclonal antibodies; lymphoma; nirmatrelvir/ritonavir; remdesivir.
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. E. A. reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Vertex Pharmaceuticals and Celgene (Bristol-Myers Squibb), Vifor Pharma, Novartis, Blue Bird Bio, Menarini Stemline, Glaxo, Regeneron, Gilead, and Novartis. M. B. reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer, bioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. D. R. G. reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Gilead, Shionogi, Pfizer, and Tillotts Pharma. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.Viruses. 2023 Oct 8;15(10):2066. doi: 10.3390/v15102066. Viruses. 2023. PMID: 37896843 Free PMC article.
-
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.BioDrugs. 2023 Sep;37(5):675-684. doi: 10.1007/s40259-023-00601-w. Epub 2023 May 6. BioDrugs. 2023. PMID: 37148526 Free PMC article.
-
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.J Infect Chemother. 2024 Aug;30(8):793-795. doi: 10.1016/j.jiac.2024.01.008. Epub 2024 Jan 17. J Infect Chemother. 2024. PMID: 38242284
-
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.Int J Infect Dis. 2023 Aug;133:53-56. doi: 10.1016/j.ijid.2023.04.412. Epub 2023 May 5. Int J Infect Dis. 2023. PMID: 37150351 Free PMC article. Review.
-
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review.Transpl Infect Dis. 2024 Jun;26(3):e14301. doi: 10.1111/tid.14301. Epub 2024 May 29. Transpl Infect Dis. 2024. PMID: 38809102 Review.
Cited by
-
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.Leukemia. 2024 Jul 23. doi: 10.1038/s41375-024-02336-1. Online ahead of print. Leukemia. 2024. PMID: 39043963
-
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.BMC Infect Dis. 2024 Jul 22;24(1):715. doi: 10.1186/s12879-024-09631-3. BMC Infect Dis. 2024. PMID: 39039440 Free PMC article.
-
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.Vaccines (Basel). 2024 Apr 25;12(5):459. doi: 10.3390/vaccines12050459. Vaccines (Basel). 2024. PMID: 38793710 Free PMC article. Review.
-
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity.Front Immunol. 2024 May 2;15:1397040. doi: 10.3389/fimmu.2024.1397040. eCollection 2024. Front Immunol. 2024. PMID: 38756784 Free PMC article. Review.
-
Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor.Med Rev (2021). 2024 Mar 4;4(2):169-171. doi: 10.1515/mr-2023-0068. eCollection 2024 Apr. Med Rev (2021). 2024. PMID: 38680682 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous